Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.

Breast cancer research and treatment - 1 Apr 2016

Evans Chalanda N, Brewer Noel T, Vadaparampil Susan T, Boisvert Marc, Ottaviano Yvonne, Lee M Catherine, Isaacs Claudine, Schwartz Marc D, O'Neill Suzanne C

Abstract excerpt

Practice guidelines incorporate genomic tumor profiling, using results such as the Oncotype DX Recurrence Score (RS), to refine recurrence risk estimates for the large proportion of breast cancer patients with early-stage, estrogen receptor-positive disease. We sought to understand the impact of receiving genomic recurrence risk estimates on breast cancer patients' well-being and the impact of these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Guideline Adherence

Share to Neoplasm Recurrence, Local

Share to Patient Reported Outcome Measures

Share to Practice Guidelines as Topic

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 27059031
DOI: 10.1007/s10549-016-3780-5
PMCID: PMC5065914

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.PMID 27059031Read ↗

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read ↗

21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Semantic proximity Read ↗

Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.Semantic proximity Read ↗

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.Semantic proximity Read ↗

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read ↗

Population‐based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 yearsSemantic proximity Read ↗

Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.Semantic proximity Read ↗

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read ↗

When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.Semantic proximity Read ↗

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read ↗

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of RecurrenceSemantic proximity Read ↗

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.